Operators are excited about a device that avoids transapical access, a limitation of other systems, says Gilbert Tang.
The everolimus scaffold, which had mostly disappeared by 3 years, was still associated with fewer reinterventions than PTA.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback